Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Verrica Pharmaceuticals Inc. (VRCA) had Revenue of $12.70M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$12.70M
Net Income	$0.20M
Cost of Goods Sold	$0.49M
Gross Profit	$12.21M
Operating Expenses	$11.19M
Operating Income	$1.51M
Non-Operating Income/Expense	$-1.31M
Pre-Tax Income	$0.20M
Normalized Pre-Tax Income	$0.20M
Income after Taxes	$0.20M
Income from Continuous Operations	$0.20M
Consolidated Net Income/Loss	$0.20M
Normalized Income after Taxes	$0.20M
EBIT	$1.51M
EBITDA	$1.71M
Weighted-Average Shares Outstanding (Basic)	9.49M
Weighted-Average Shares Outstanding (Diluted)	9.49M
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$36.78M
Property, Plant, and Equipment	$0.32M
Long-Term Assets	$2.33M
Total Assets	$39.11M
Current Liabilities	$29.22M
Long-Term Debt	$25.16M
Long-Term Liabilities	$27.37M
Total Liabilities	$56.59M
Common Equity	$-17.48M
Tangible Shareholders Equity	$-17.48M
Shareholders Equity	$-17.48M
Common Shares Outstanding	9.25M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-22.72M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$-8.21M
Beginning Cash	$46.33M
End Cash	$15.40M
Increase/Decrease in Cash	$-30.93M
Stock-Based Compensation	$1.91M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.26
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	3.28
Debt to Equity Ratio	-2.18
Gross Margin	96.11%
Operating Margin	11.89%
EBIT Margin	11.89%
EBITDA Margin	--
Pre-Tax Profit Margin	1.61%
Profit Margin	1.61%
Free Cash Flow	$-22.72M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.32
Inventory Turnover	0.20
Receiveable Turnover	0.73
Days Sales in Receivables	123.08
Return on Equity	-1.17%
Return on Tangible Equity	-1.17%
Return on Assets	0.52%
Return on Investments	2.66%
Book Value Per Share	$-1.89
Free Cash Flow per Share	$-2.39
Operating Cash Flow per Share	$-2.39

Data from Zacks Investment Research, Inc.